Combination of interferon beta - 1a and ribavirin has superior viral suppression than interferon beta - 1a alone both at the end of treatment and 6 months after stopping treatment table 在完成24周治療及完成治療六個(gè)月后發(fā)現(xiàn),干擾素beta - 1a及利巴韋林的聯(lián)合療法則比干擾素beta - 1a的單一療法有更強(qiáng)的病毒抑制作用(見表) 。
257 asian chronic hepatitis c patients with active disease were recruited and randomly assigned in 1 : 1 ratio to receive interferon beta - 1a or placebo treatment for 12 weeks in a double - blinded manner 研究招募了二百五十七名亞裔慢性丙型肝炎病人,以一比一的比例隨機(jī)分為兩組,分別注射干擾素beta - 1a或安慰劑,進(jìn)行十二周的雙盲研究。
In summary , interferon beta - 1a and ribavirin combination treatment can achieve a similar rate of viral clearance but a low rate of adverse event and patient discontinuation as compared to the existing peginterferon - alfa based treatment 總括而言,比較聚乙二醇干擾素,干擾素beta - 1a能達(dá)至相約的病毒清除效果,但就為病人帶來更小的副作用和減低停藥的機(jī)會(huì)。
At week 12 , patients on interferon beta - 1a would receive 12 more weeks of interferon - beta - 1 while patients on placebo would receive 24 weeks of interferon beta - 1a and ribavirin combination treatment . interferon beta - 1a has superior viral suppression than placebo at week 12 在第十二周,注射干擾素beta - 1a的病人會(huì)多接受十二周的干擾素beta - 1a治療,而使用安慰劑的病人則會(huì)接受二十四周的干擾素beta - 1a及利巴韋林聯(lián)合療法。